The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Research Report 2025
Synopsis
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
The global Chemotherapy-Induced Nausea and Vomiting (CINV) market was valued at US$ 2567.6 million in 2023 and is anticipated to reach US$ 3044.6 million by 2030, witnessing a CAGR of 2.5% during the forecast period 2024-2030.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
This report aims to provide a comprehensive presentation of the global market for Chemotherapy-Induced Nausea and Vomiting (CINV), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy-Induced Nausea and Vomiting (CINV).
Report Scope
The Chemotherapy-Induced Nausea and Vomiting (CINV) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chemotherapy-Induced Nausea and Vomiting (CINV) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chemotherapy-Induced Nausea and Vomiting (CINV) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Segment by Type
CINV
PONV
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
The global Chemotherapy-Induced Nausea and Vomiting (CINV) market was valued at US$ 2567.6 million in 2023 and is anticipated to reach US$ 3044.6 million by 2030, witnessing a CAGR of 2.5% during the forecast period 2024-2030.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
This report aims to provide a comprehensive presentation of the global market for Chemotherapy-Induced Nausea and Vomiting (CINV), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy-Induced Nausea and Vomiting (CINV).
Report Scope
The Chemotherapy-Induced Nausea and Vomiting (CINV) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chemotherapy-Induced Nausea and Vomiting (CINV) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chemotherapy-Induced Nausea and Vomiting (CINV) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Segment by Type
CINV
PONV
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chemotherapy-Induced Nausea and Vomiting (CINV) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CINV
1.2.3 PONV
1.3 Market by Application
1.3.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Perspective (2019-2030)
2.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Growth Trends by Region
2.2.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Region (2019-2024)
2.2.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Region (2025-2030)
2.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Dynamics
2.3.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Industry Trends
2.3.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Drivers
2.3.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Challenges
2.3.4 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chemotherapy-Induced Nausea and Vomiting (CINV) Players by Revenue
3.1.1 Global Top Chemotherapy-Induced Nausea and Vomiting (CINV) Players by Revenue (2019-2024)
3.1.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Players (2019-2024)
3.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue
3.4 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Concentration Ratio
3.4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue in 2023
3.5 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players Head office and Area Served
3.6 Key Players Chemotherapy-Induced Nausea and Vomiting (CINV) Product Solution and Service
3.7 Date of Enter into Chemotherapy-Induced Nausea and Vomiting (CINV) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chemotherapy-Induced Nausea and Vomiting (CINV) Breakdown Data by Type
4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Type (2019-2024)
4.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Type (2025-2030)
5 Chemotherapy-Induced Nausea and Vomiting (CINV) Breakdown Data by Application
5.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Historic Market Size by Application (2019-2024)
5.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2019-2030)
6.2 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2019-2024)
6.4 North America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2019-2030)
7.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2019-2024)
7.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2019-2030)
8.2 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region (2019-2024)
8.4 Asia-Pacific Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2019-2030)
9.2 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2019-2024)
9.4 Latin America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2019-2030)
10.2 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2019-2024)
10.4 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.1.4 Merck Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Eisai
11.2.1 Eisai Company Detail
11.2.2 Eisai Business Overview
11.2.3 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.2.4 Eisai Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.2.5 Eisai Recent Development
11.3 ProStrakan
11.3.1 ProStrakan Company Detail
11.3.2 ProStrakan Business Overview
11.3.3 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.3.4 ProStrakan Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.3.5 ProStrakan Recent Development
11.4 Helsinn Holding
11.4.1 Helsinn Holding Company Detail
11.4.2 Helsinn Holding Business Overview
11.4.3 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.4.4 Helsinn Holding Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.4.5 Helsinn Holding Recent Development
11.5 Mundipharma
11.5.1 Mundipharma Company Detail
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.5.4 Mundipharma Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.5.5 Mundipharma Recent Development
11.6 Qilu Pharma
11.6.1 Qilu Pharma Company Detail
11.6.2 Qilu Pharma Business Overview
11.6.3 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.6.4 Qilu Pharma Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.6.5 Qilu Pharma Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.7.4 Teva Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.7.5 Teva Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.8.4 Novartis Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 Heron Therapeutics
11.9.1 Heron Therapeutics Company Detail
11.9.2 Heron Therapeutics Business Overview
11.9.3 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.9.4 Heron Therapeutics Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.9.5 Heron Therapeutics Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.10.4 Roche Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.10.5 Roche Recent Development
11.11 Mylan
11.11.1 Mylan Company Detail
11.11.2 Mylan Business Overview
11.11.3 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.11.4 Mylan Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.11.5 Mylan Recent Development
11.12 Tesaro
11.12.1 Tesaro Company Detail
11.12.2 Tesaro Business Overview
11.12.3 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
11.12.4 Tesaro Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2019-2024)
11.12.5 Tesaro Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
